Literature DB >> 25315186

Prognostic value of cyclin B in endometrial endometrioid adenocarcinoma.

Simi Santala1, Anne Talvensaari-Mattila, Ylermi Soini, Markku Santala.   

Abstract

Cyclins are a group of cell cycle regulatory proteins. Cyclin B acts as an activator to cyclin-dependent kinase 1 (CDK1), a protein kinase essential for G2/M phase transition. Deregulation of cyclins has been linked to a number of malignant neoplasms, but the impact on clinicopathological parameters seems to be cancer-specific. Overexpression of cyclin B has been shown to affect survival in some malignant tumors, including breast and esophageal cancer, but its impact on endometrial cancer has not been extensively studied. For this study, 211 endometrial endometrioid adenocarcinoma samples were obtained from patients surgically treated at the Oulu University Hospital. The samples were immunohistochemically stained and analyzed for cyclin B expression. The relationships between cyclin B expression and conventional prognostic factors were analyzed. A discrimination threshold for survival analyses was calculated by utilizing the receiver operator characteristic (ROC) method. Cyclin B expression correlated with grade and advanced stage. Survival analyses showed that cyclin B expression affects cancer-specific survival in univariate analysis. In multivariate analysis, the results were indicative that cyclin B may hold independent prognostic significance, but further studies are required to assess this.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25315186     DOI: 10.1007/s13277-014-2676-4

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  26 in total

1.  Revised FIGO staging for carcinoma of the endometrium.

Authors:  William Creasman
Journal:  Int J Gynaecol Obstet       Date:  2009-04-03       Impact factor: 3.561

Review 2.  Meta-analysis for cyclin E in lung cancer survival.

Authors:  Li-nian Huang; Dong-sheng Wang; Yu-qing Chen; Wei Li; Feng-dan Hu; Bei-lei Gong; Cheng-Ling Zhao; Wei Jia
Journal:  Clin Chim Acta       Date:  2012-01-09       Impact factor: 3.786

Review 3.  Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review.

Authors:  Sunil Singhal; Anil Vachani; Danielle Antin-Ozerkis; Larry R Kaiser; Steven M Albelda
Journal:  Clin Cancer Res       Date:  2005-06-01       Impact factor: 12.531

Review 4.  Tissue and serum biomarkers as prognostic variables in endometrioid-type endometrial cancer.

Authors:  Angiolo Gadducci; Stefania Cosio; Andrea Riccardo Genazzani
Journal:  Crit Rev Oncol Hematol       Date:  2010-12-04       Impact factor: 6.312

5.  Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population-based lymph node negative breast cancer cohort.

Authors:  E Niméus-Malmström; A Koliadi; C Ahlin; M Holmqvist; L Holmberg; R-M Amini; K Jirström; F Wärnberg; C Blomqvist; M Fernö; M-L Fjällskog
Journal:  Int J Cancer       Date:  2010-08-15       Impact factor: 7.396

6.  The impact of cyclin D1 overexpression on the prognosis of ER-positive breast cancers: a meta-analysis.

Authors:  Xiao-Ling Xu; Shu-Zheng Chen; Wei Chen; Wei-Hui Zheng; Xiang-Hou Xia; Hong-Jian Yang; Bo Li; Wei-Min Mao
Journal:  Breast Cancer Res Treat       Date:  2013-05-14       Impact factor: 4.872

7.  Progressive derailment of cell cycle regulators in endometrial carcinogenesis.

Authors:  N Horrée; P J van Diest; P van der Groep; D M D S Sie-Go; A P M Heintz
Journal:  J Clin Pathol       Date:  2007-05-04       Impact factor: 3.411

8.  Expression and prognostic significance of cyclin B1 and cyclin A in non-small cell lung cancer.

Authors:  Wendy A Cooper; Maija R J Kohonen-Corish; Brian McCaughan; Catherine Kennedy; Robert L Sutherland; Cheok Soon Lee
Journal:  Histopathology       Date:  2009-07       Impact factor: 5.087

Review 9.  Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis.

Authors:  Bonnie E Gould Rothberg; Michael B Bracken; David L Rimm
Journal:  J Natl Cancer Inst       Date:  2009-03-24       Impact factor: 13.506

10.  High cyclin B1 expression is associated with poor survival in breast cancer.

Authors:  K Aaltonen; R-M Amini; P Heikkilä; K Aittomäki; A Tamminen; H Nevanlinna; C Blomqvist
Journal:  Br J Cancer       Date:  2009-03-17       Impact factor: 7.640

View more
  5 in total

1.  Insulin is an important risk factor of endometrial cancer among premenopausal women: a case-control study in China.

Authors:  Yanli Shao; Shijie Cheng; Jianqing Hou; Ying Zuo; Wei Zheng; Min Xia; Nan Mu
Journal:  Tumour Biol       Date:  2015-10-29

2.  Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4.

Authors:  Jason Roszik; Anil K Sood; Alejandro Villar-Prados; Sherry Y Wu; Karem A Court; Shaolin Ma; Christopher LaFargue; Mamur A Chowdhury; Margaret I Engelhardt; Cristina Ivan; Prahlad T Ram; Ying Wang; Keith Baggerly; Cristian Rodriguez-Aguayo; Gabriel Lopez-Berestein; Shyh Ming-Yang; David J Maloney; Makoto Yoshioka; Jeffrey W Strovel
Journal:  Mol Cancer Ther       Date:  2018-11-12       Impact factor: 6.261

3.  The landscape of gene co-expression modules correlating with prognostic genetic abnormalities in AML.

Authors:  Chao Guo; Ya-Yue Gao; Qian-Qian Ju; Chun-Xia Zhang; Ming Gong; Zhen-Ling Li
Journal:  J Transl Med       Date:  2021-05-29       Impact factor: 5.531

4.  Integrated analysis of genome-wide DNA methylation, gene expression and protein expression profiles in molecular subtypes of WHO II-IV gliomas.

Authors:  Zhi-Liang Wang; Chuan-Bao Zhang; Jin-Quan Cai; Qing-Bin Li; Zheng Wang; Tao Jiang
Journal:  J Exp Clin Cancer Res       Date:  2015-10-26

5.  Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) Promotes Uterine Serous Cancer Cell Proliferation and Cell Cycle Progression.

Authors:  Suet-Ying Kwan; Chi-Lam Au-Yeung; Tsz-Lun Yeung; Angela Rynne-Vidal; Kwong-Kwok Wong; John I Risinger; Hui-Kuan Lin; Rosemarie E Schmandt; Melinda S Yates; Samuel C Mok; Karen H Lu
Journal:  Cancers (Basel)       Date:  2020-01-02       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.